https://médecine.top/index.php?action=history&feed=atom&title=Glom%C3%A9rulopathies
Glomérulopathies - Historique des versions
2026-09-03T19:11:56Z
Historique des révisions pour cette page sur le wiki
MediaWiki 1.35.2
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=5584&oldid=prev
Julien : /* Glomérulonéphrite extra-membraneuse */
2026-03-26T14:08:40Z
<p><span dir="auto"><span class="autocomment">Glomérulonéphrite extra-membraneuse</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 mars 2026 à 14:08</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l81" >Ligne 81 :</td>
<td colspan="2" class="diff-lineno">Ligne 81 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Glomérulonéphrite extra-membraneuse ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Glomérulonéphrite extra-membraneuse ===</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* Lésion principale: podocyte et membrane basale glomérulaire</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <ins class="diffchange diffchange-inline"><u></ins>Lésion principale:<ins class="diffchange diffchange-inline"></u> </ins>podocyte et membrane basale glomérulaire</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* Mécanisme: auto-immun (complexes immuns et IgG in situ)</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <ins class="diffchange diffchange-inline"><u></ins>Mécanisme:<ins class="diffchange diffchange-inline"></u> </ins>auto-immun (complexes immuns et IgG in situ)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Diagnostic:</u> biopsie, '''dosage des anticorps anti-phospholipase A2 (PLA2)'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Diagnostic:</u> biopsie, '''dosage des anticorps anti-phospholipase A2 (PLA2)'''</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement non spécifique néphroprotecteur:</u> IEC/ARA (protection de la fonction rénale), diurétique (contrôle de l'oedème) et hypolipémiant selon profil lipidique</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement non spécifique néphroprotecteur:</u> IEC/ARA (protection de la fonction rénale), diurétique (contrôle de l'oedème) et hypolipémiant selon profil lipidique</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=5583&oldid=prev
Julien : /* Minimal Change Disease (MCD) */
2026-03-26T14:08:14Z
<p><span dir="auto"><span class="autocomment">Minimal Change Disease (MCD)</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 mars 2026 à 14:08</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l98" >Ligne 98 :</td>
<td colspan="2" class="diff-lineno">Ligne 98 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Minimal Change Disease (MCD) ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Minimal Change Disease (MCD) ===</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* Bon pronostic</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Primaire ====</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Primaire ====</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Secondaire ====</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Secondaire ====</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=5071&oldid=prev
Julien : /* Néphropathie à IgA */
2024-03-28T08:10:29Z
<p><span dir="auto"><span class="autocomment">Néphropathie à IgA</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 28 mars 2024 à 08:10</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l56" >Ligne 56 :</td>
<td colspan="2" class="diff-lineno">Ligne 56 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Antiproteinuric therapy using an '''ACE inhibitor or angiotensin receptor blocker (ARB)''' is the hallmark for treating IgA nephropathy and remains the most proven therapy in slowing progression of the disease.</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Antiproteinuric therapy using an '''ACE inhibitor or angiotensin receptor blocker (ARB)''' is the hallmark for treating IgA nephropathy and remains the most proven therapy in slowing progression of the disease.</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">** iSGLT-2, corticostéroïdes/budésonide, ...</ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* <u>Suivi:</u></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">** '''Protéinurie (cible <1g/24h)''', (suivi en % des érythrocytes glomérulaires)</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Glomérulonéphrite post-infectieuse ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Glomérulonéphrite post-infectieuse ===</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=5070&oldid=prev
Julien : /* Néphropathie à IgA */
2024-03-28T07:58:17Z
<p><span dir="auto"><span class="autocomment">Néphropathie à IgA</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 28 mars 2024 à 07:58</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l51" >Ligne 51 :</td>
<td colspan="2" class="diff-lineno">Ligne 51 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><u>Synonyme:</u> maladie de Berger</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><u>Synonyme:</u> maladie de Berger</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Epidémiologie:</u> maladie glomérulaire la plus répandue au monde<ref>https://www.revmed.ch/revue-medicale-suisse/2024/revue-medicale-suisse-863/nephropathie-a-iga-le-debut-d-une-nouvelle-ere-therapeutique</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Epidémiologie:</u> maladie glomérulaire la plus répandue au monde<ref>https://www.revmed.ch/revue-medicale-suisse/2024/revue-medicale-suisse-863/nephropathie-a-iga-le-debut-d-une-nouvelle-ere-therapeutique</ref></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* <u>Physiopathologie:</u> dépôts mésangiaux d'IgA aberrants qui entraînent une inflammation locale, aboutissant à des lésions glomérulaires constituées, responsables d’une fuite de protéines et d’hématies dans l’urine<ref>RevMed</u></ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Clinique:</u> Recurrent gross hematuria, in which macroscopic hematuria occurs in the setting of an upper respiratory infection (synpharyngitic hematuria) is a common presentation in younger patients</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Clinique:</u> Recurrent gross hematuria, in which macroscopic hematuria occurs in the setting of an upper respiratory infection (synpharyngitic hematuria) is a common presentation in younger patients</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Diagnostic:</u> '''biopsie'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Diagnostic:</u> '''biopsie'''</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=5069&oldid=prev
Julien : /* Néphropathie à IgA */
2024-03-28T07:56:45Z
<p><span dir="auto"><span class="autocomment">Néphropathie à IgA</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 28 mars 2024 à 07:56</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l50" >Ligne 50 :</td>
<td colspan="2" class="diff-lineno">Ligne 50 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Néphropathie à IgA ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Néphropathie à IgA ===</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><u>Synonyme:</u> maladie de Berger</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><u>Synonyme:</u> maladie de Berger</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* <u>Epidémiologie:</u> maladie glomérulaire la plus répandue au monde<ref>https://www.revmed.ch/revue-medicale-suisse/2024/revue-medicale-suisse-863/nephropathie-a-iga-le-debut-d-une-nouvelle-ere-therapeutique</ref></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* <u>Clinique:</u> Recurrent gross hematuria, in which macroscopic hematuria occurs in the setting of an upper respiratory infection (synpharyngitic hematuria) is a common presentation in younger patients</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Diagnostic:</u> '''biopsie'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Diagnostic:</u> '''biopsie'''</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <del class="diffchange diffchange-inline">Recurrent gross hematuria, in which macroscopic hematuria occurs in the setting of an upper respiratory infection (synpharyngitic hematuria) is a common presentation in younger patients</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <ins class="diffchange diffchange-inline"><u>Traitement:</u></ins></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* Antiproteinuric therapy using an ACE inhibitor or angiotensin receptor blocker (ARB) is the hallmark for treating IgA nephropathy and remains the most proven therapy in slowing progression of the disease.</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">*</ins>* Antiproteinuric therapy using an <ins class="diffchange diffchange-inline">'''</ins>ACE inhibitor or angiotensin receptor blocker (ARB)<ins class="diffchange diffchange-inline">''' </ins>is the hallmark for treating IgA nephropathy and remains the most proven therapy in slowing progression of the disease.</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Glomérulonéphrite post-infectieuse ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Glomérulonéphrite post-infectieuse ===</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=4858&oldid=prev
Julien : /* Glomérulonéphrite extra-membraneuse */
2023-10-10T11:04:59Z
<p><span dir="auto"><span class="autocomment">Glomérulonéphrite extra-membraneuse</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 10 octobre 2023 à 11:04</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l77" >Ligne 77 :</td>
<td colspan="2" class="diff-lineno">Ligne 77 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Lésion principale: podocyte et membrane basale glomérulaire</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Lésion principale: podocyte et membrane basale glomérulaire</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Mécanisme: auto-immun (complexes immuns et IgG in situ)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Mécanisme: auto-immun (complexes immuns et IgG in situ)</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* Diagnostic: biopsie, '''dosage des anticorps anti-phospholipase A2 (PLA2)'''</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <ins class="diffchange diffchange-inline"><u></ins>Diagnostic:<ins class="diffchange diffchange-inline"></u> </ins>biopsie, '''dosage des anticorps anti-phospholipase A2 (PLA2)'''</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement non spécifique néphroprotecteur:</u> IEC/ARA (protection de la fonction rénale), diurétique (contrôle de l'oedème) et hypolipémiant selon profil lipidique</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement non spécifique néphroprotecteur:</u> IEC/ARA (protection de la fonction rénale), diurétique (contrôle de l'oedème) et hypolipémiant selon profil lipidique</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complications:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complications:</u></div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=4857&oldid=prev
Julien : /* Néphropathie à IgA */
2023-10-10T11:03:40Z
<p><span dir="auto"><span class="autocomment">Néphropathie à IgA</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 10 octobre 2023 à 11:03</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l50" >Ligne 50 :</td>
<td colspan="2" class="diff-lineno">Ligne 50 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Néphropathie à IgA ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Néphropathie à IgA ===</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><u>Synonyme:</u> maladie de Berger</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><u>Synonyme:</u> maladie de Berger</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* <u>Diagnostic:</u> '''biopsie'''</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Recurrent gross hematuria, in which macroscopic hematuria occurs in the setting of an upper respiratory infection (synpharyngitic hematuria) is a common presentation in younger patients</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Recurrent gross hematuria, in which macroscopic hematuria occurs in the setting of an upper respiratory infection (synpharyngitic hematuria) is a common presentation in younger patients</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Antiproteinuric therapy using an ACE inhibitor or angiotensin receptor blocker (ARB) is the hallmark for treating IgA nephropathy and remains the most proven therapy in slowing progression of the disease.</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Antiproteinuric therapy using an ACE inhibitor or angiotensin receptor blocker (ARB) is the hallmark for treating IgA nephropathy and remains the most proven therapy in slowing progression of the disease.</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=4856&oldid=prev
Julien : /* Glomérulonéphrite post-infectieuse */
2023-10-10T11:02:53Z
<p><span dir="auto"><span class="autocomment">Glomérulonéphrite post-infectieuse</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 10 octobre 2023 à 11:02</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l55" >Ligne 55 :</td>
<td colspan="2" class="diff-lineno">Ligne 55 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Glomérulonéphrite post-infectieuse ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Glomérulonéphrite post-infectieuse ===</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Diagnostic:</u> '''Fraction C3 du complément abaissée dans 90% des cas''', biopsie rénale à discuter</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Diagnostic:</u> '''Fraction C3 du complément abaissée dans 90% des cas''', biopsie rénale à discuter</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* Traitement: cause sous-jacente, glucocorticoïdes</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <ins class="diffchange diffchange-inline"><u></ins>Traitement:<ins class="diffchange diffchange-inline"></u> </ins>cause sous-jacente, glucocorticoïdes</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Forme à début aigu curable ====</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Forme à début aigu curable ====</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Forme à début aigu d'évolution chronique ====</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Forme à début aigu d'évolution chronique ====</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=4855&oldid=prev
Julien : /* Néphropathie à IgA */
2023-10-10T11:01:35Z
<p><span dir="auto"><span class="autocomment">Néphropathie à IgA</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 10 octobre 2023 à 11:01</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l49" >Ligne 49 :</td>
<td colspan="2" class="diff-lineno">Ligne 49 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Treatment for anti-GBM disease consists of plasmapheresis, pulse glucocorticoids (high doses of intravenous glucocorticoids over a short period of time) followed by oral prednisone, and cyclophosphamide.</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Treatment for anti-GBM disease consists of plasmapheresis, pulse glucocorticoids (high doses of intravenous glucocorticoids over a short period of time) followed by oral prednisone, and cyclophosphamide.</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Néphropathie à IgA ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Néphropathie à IgA ===</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><u>Synonyme:</u> maladie de Berger</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Recurrent gross hematuria, in which macroscopic hematuria occurs in the setting of an upper respiratory infection (synpharyngitic hematuria) is a common presentation in younger patients</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Recurrent gross hematuria, in which macroscopic hematuria occurs in the setting of an upper respiratory infection (synpharyngitic hematuria) is a common presentation in younger patients</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Antiproteinuric therapy using an ACE inhibitor or angiotensin receptor blocker (ARB) is the hallmark for treating IgA nephropathy and remains the most proven therapy in slowing progression of the disease.</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Antiproteinuric therapy using an ACE inhibitor or angiotensin receptor blocker (ARB) is the hallmark for treating IgA nephropathy and remains the most proven therapy in slowing progression of the disease.</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Glom%C3%A9rulopathies&diff=2891&oldid=prev
Julien : /* Glomérulonéphrite extra-membraneuse */
2020-06-24T09:41:29Z
<p><span dir="auto"><span class="autocomment">Glomérulonéphrite extra-membraneuse</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 24 juin 2020 à 09:41</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l77" >Ligne 77 :</td>
<td colspan="2" class="diff-lineno">Ligne 77 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Diagnostic: biopsie, '''dosage des anticorps anti-phospholipase A2 (PLA2)'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Diagnostic: biopsie, '''dosage des anticorps anti-phospholipase A2 (PLA2)'''</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement non spécifique néphroprotecteur:</u> IEC/ARA (protection de la fonction rénale), diurétique (contrôle de l'oedème) et hypolipémiant selon profil lipidique</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement non spécifique néphroprotecteur:</u> IEC/ARA (protection de la fonction rénale), diurétique (contrôle de l'oedème) et hypolipémiant selon profil lipidique</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complications:</u> In a large retrospective cohort of clotting complications in membranous glomerulopathy, >70% of the clots occurred within 2 years of diagnosis, and the risk of clotting markedly increased once albumin levels dropped below 2.8 g/dL (28 g/L) (OR, 2.53; P = 0.02, compared with albumin ≥2.8 g/dL [28 g/L]).</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complications:</u></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">** '''Thrombophilie (en particulier de la veine rénale)''' → </ins>In a large retrospective cohort of clotting complications in membranous glomerulopathy, >70% of the clots occurred within 2 years of diagnosis, and the risk of clotting markedly increased once albumin levels dropped below 2.8 g/dL (28 g/L) (OR, 2.53; P = 0.02, compared with albumin ≥2.8 g/dL [28 g/L]).</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Forme primaire ====</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Forme primaire ====</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Patients with newly diagnosed primary forms of membranous glomerulopathy are usually observed for 6 to 12 months on conservative therapy (renin-angiotensin system blockade, cholesterol-lowering medication, and edema management) before initiating a course of immunosuppression for patients with persistent nephrotic-range proteinuria. The observation period allows patients a chance to achieve spontaneous remission, which occurs in approximately 30% within 1 to 2 years of diagnosis.</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Patients with newly diagnosed primary forms of membranous glomerulopathy are usually observed for 6 to 12 months on conservative therapy (renin-angiotensin system blockade, cholesterol-lowering medication, and edema management) before initiating a course of immunosuppression for patients with persistent nephrotic-range proteinuria. The observation period allows patients a chance to achieve spontaneous remission, which occurs in approximately 30% within 1 to 2 years of diagnosis.</div></td></tr>
</table>
Julien